Genmab CEO lands USD 6.8m salary in 2021

After three years with results in line with analysts’ expectations, the CEO of Danish biotech company Genmab has received a raise, bringing his 2021 wages to DKK 44.3m (USD 6.8m).

Photo: Mik Eskestad/ERH

CEO at Genmab Jan van de Winkel’s wallet has become thicker again this year, following a 2021 in which the Danish biotech company largely lived up to expectations with a revenue of DKK 8.5bn (USD 1.3bn) and an operating profit (EBIT) of DKK 3bn (USD 461m).

In 2021, van de Winkel was compensated with DKK 44.3m (USD USD 6.8m) from his duties at the helm, up from DKK 37.3m (USD 5.7m) in 2020, a raise of of 18.7 percent.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs